AAAAAA
Results:
1-12
|
Results: 12
Authors:
Pierga, JY
Robain, M
Jouve, M
Asselain, B
Dieras, V
Beuzeboc, P
Palangie, T
Dorval, T
Extra, JM
Scholl, S
Pouillart, P
Citation: Jy. Pierga et al., Response to chemotherapy is a major parameter-influencing long-term survival of metastatic breast cancer patients, ANN ONCOL, 12(2), 2001, pp. 231-237
Authors:
Rouzier, R
Extra, JM
Carton, M
Falcou, MC
Vincent-Salomon, A
Fourquet, A
Pouillart, P
Bourstyn, E
Citation: R. Rouzier et al., Primary chemotherapy for operable breast cancer: Incidence and prognostic significance of ipsilateral breast tumor recurrence after breast-conservingsurgery, J CL ONCOL, 19(18), 2001, pp. 3828-3835
Authors:
Cottu, PH
Extra, JM
Espie, M
Marolleau, J
de Roquancourt, A
Makke, J
Miclea, JM
Laurence, V
Mayeur, D
Lerebours, F
Cuvier, C
Marty, M
Citation: Ph. Cottu et al., High-dose sequential epirubicin and cyclophosphamide with peripheral bloodstem cell support for advanced breast cancer: results of a phase II study, BR J CANC, 85(9), 2001, pp. 1240-1246
Authors:
de Cremoux, P
Extra, JM
Denis, MG
Pierga, JY
Bourstyn, E
Nos, C
Clough, KB
Boudou, E
Martin, EC
Muller, A
Pouillart, P
Magdelenat, H
Citation: P. De Cremoux et al., Detection of MUC1-expressing mammary carcinoma cells in the peripheral blood of breast cancer patients by real-time polymerase chain reaction, CLIN CANC R, 6(8), 2000, pp. 3117-3122
Authors:
Robain, M
Pierga, JY
Jouve, M
Asselain, B
Dieras, V
Beuzeboc, P
Palangie, T
Dorval, T
Extra, JM
Scholl, S
Pouillart, P
Citation: M. Robain et al., Predictive factors of response to first-line chemotherapy in 1426 women with metastatic breast cancer, EUR J CANC, 36(18), 2000, pp. 2301-2312
Authors:
Cottu, PH
Cojean-Zelek, I
Bourstyn, E
de Roquancourt, A
Extra, JM
Perret, F
Gorins, A
Marty, M
Espie, M
Citation: Ph. Cottu et al., Retrospective multivariate analysis of radio-pathological correlation of impalpable breast lesions. Hospital Saint-Louis's experience., REV MED IN, 21(4), 2000, pp. 337-343
Authors:
Livartowski, A
Beuzeboc, P
Le Vu, B
Courbard, M
Pierga, JY
Extra, JM
Scholl, S
Pouillart, P
Citation: A. Livartowski et al., Budgeting novel anti-cancer drugs: with which resources?, B CANCER, 87(10), 2000, pp. 745-754
Authors:
Pierga, JY
Mouret, E
Dieras, V
Laurence, V
Beuzeboc, P
Dorval, T
Palangie, T
Jouve, M
Vincent-Salomon, A
Scholl, S
Extra, JM
Asselain, B
Pouillart, P
Citation: Jy. Pierga et al., Prognostic value of persistent node involvement after neoadjuvant chemotherapy in patients with operable breast cancer, BR J CANC, 83(11), 2000, pp. 1480-1487
Authors:
Faivre, S
Kalla, S
Cvitkovic, E
Bourdon, O
Hauteville, D
Dourte, LM
Bensmaine, MA
Itzhaki, M
Marty, M
Extra, JM
Citation: S. Faivre et al., Oxaliplatin and paclitaxel combination in patients with platinum-pretreated ovarian carcinoma: An investigator-originated compassionate-use experience, ANN ONCOL, 10(9), 1999, pp. 1125-1128
Authors:
Cottu, PH
Zelek, L
Extra, JM
Espie, M
Mignot, L
Morvan, F
Marty, M
Citation: Ph. Cottu et al., High-dose epirubicin and cyclophosphamide every two weeks as first-line chemotherapy for relapsing metastatic breast cancer patients, ANN ONCOL, 10(7), 1999, pp. 795-801
Authors:
Houze, P
Bellik, B
Extra, JM
Bouro, F
Bousquet, B
Citation: P. Houze et al., Urinary carboxyterminal telopeptide of collagen I as a potential marker ofbone metastases chemotherapy monitoring in breast cancer, CLIN CHIM A, 281(1-2), 1999, pp. 77-88
Authors:
Cottu, PH
Extra, JM
Lerebours, F
Espie, M
Marty, M
Citation: Ph. Cottu et al., Clinical activity of irinotecan, B CANCER, 1998, pp. 21-25
Risultati:
1-12
|